Found: 12
Select item for more details and to access through your institution.
Impact of CYP2D6*2, CYP2D6*35, rs5758550, and related haplotypes on risperidone clearance in vivo.
- Published in:
- European Journal of Clinical Pharmacology, 2024, v. 80, n. 10, p. 1531, doi. 10.1007/s00228-024-03721-6
- By:
- Publication type:
- Article
Low-target tacrolimus in de novo standard risk renal transplant recipients: A single-centre experience.
- Published in:
- Nephrology, 2016, v. 21, n. 10, p. 821, doi. 10.1111/nep.12738
- By:
- Publication type:
- Article
Prediction of CYP2D6 poor metabolizers by measurements of solanidine and metabolites—a study in 839 patients with known CYP2D6 genotype.
- Published in:
- European Journal of Clinical Pharmacology, 2023, v. 79, n. 4, p. 523, doi. 10.1007/s00228-023-03462-y
- By:
- Publication type:
- Article
Importance of hematocrit for a tacrolimus target concentration strategy.
- Published in:
- European Journal of Clinical Pharmacology, 2014, v. 70, n. 1, p. 65, doi. 10.1007/s00228-013-1584-7
- By:
- Publication type:
- Article
Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling.
- Published in:
- British Journal of Clinical Pharmacology, 2014, v. 78, n. 3, p. 509, doi. 10.1111/bcp.12361
- By:
- Publication type:
- Article
Effect of the NFIB rs28379954 T>C polymorphism on CYP2D6‐catalyzed metabolism of solanidine.
- Published in:
- CTS: Clinical & Translational Science, 2024, v. 17, n. 2, p. 1, doi. 10.1111/cts.13743
- By:
- Publication type:
- Article
Evidence for solanidine as a dietary CYP2D6 biomarker: Significant correlation with risperidone metabolism.
- Published in:
- British Journal of Clinical Pharmacology, 2024, v. 90, n. 3, p. 740, doi. 10.1111/bcp.15721
- By:
- Publication type:
- Article
The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation.
- Published in:
- British Journal of Clinical Pharmacology, 2017, v. 83, n. 7, p. 1457, doi. 10.1111/bcp.13248
- By:
- Publication type:
- Article
Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance.
- Published in:
- British Journal of Clinical Pharmacology, 2017, v. 83, n. 6, p. 1350, doi. 10.1111/bcp.13188
- By:
- Publication type:
- Article
Response to: 'Response to: Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance'.
- Published in:
- British Journal of Clinical Pharmacology, 2017, v. 83, n. 6, p. 1357, doi. 10.1111/bcp.13276
- By:
- Publication type:
- Article
Inclusion of CYP3 A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation.
- Published in:
- Transplant International, 2013, v. 26, n. 12, p. 1198, doi. 10.1111/tri.12194
- By:
- Publication type:
- Article
Dopamine agonist serum concentrations and impulse control disorders in Parkinson's disease.
- Published in:
- European Journal of Neurology, 2024, v. 31, n. 2, p. 1, doi. 10.1111/ene.16144
- By:
- Publication type:
- Article